Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin/Linagliptin FDC vs Empagliflozin in Japanese T2DM
NCT02489968Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2015
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of linagliptin in type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Started May 2015; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02489968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02489968.